Skip to main
AXSM

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics (AXSM) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 53%
Buy 47%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axsome Therapeutics Inc. reported third-quarter revenues of $136.1 million, surpassing analyst expectations and reflecting a robust year-over-year growth of 69% alongside a sequential increase of 14%. The company has enhanced payer coverage to 85%, which sets a positive foundation for future sales growth, particularly with ongoing clinical studies that address unmet needs in CNS disorders. With projections indicating faster revenue growth compared to operating costs, Axsome anticipates achieving cash flow positivity by 2026, bolstered by strong performance from its product pipeline.

Bears say

Axsome Therapeutics faces a challenging outlook largely due to a modest decrease in its full-year 2025 revenue forecast, which reflects ongoing risks such as lower-than-expected market access for its product AUVELITY and setbacks in clinical trials for key candidates like AXS-05. The company has encountered significant setbacks, including a failed Phase 3 trial for major depressive disorder and potential delays in securing regulatory approvals for its pipeline products, AXS-12 and AXS-14. Furthermore, heightened competition and lower market penetration could lead to reduced commercial success, alongside concerns of long-term dilution risk, impacting investor confidence.

Axsome Therapeutics (AXSM) has been analyzed by 17 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 47% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Axsome Therapeutics (AXSM) Forecast

Analysts have given Axsome Therapeutics (AXSM) a Buy based on their latest research and market trends.

According to 17 analysts, Axsome Therapeutics (AXSM) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $177.76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $177.76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Axsome Therapeutics (AXSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.